Zynerba Pharmaceuticals (ZYNE) Cash & Debt
Zynerba Pharmaceuticals (ZYNE) has $0 in cash and equivalents with $0 in total debt, resulting in a net cash position of $0.
Cash & Equivalents
$0
Total Debt
$0
Net Cash
$0
Cash Runway
—
Quarterly Balance Sheet
| Period | Cash | Total Debt | Net Cash | Total Assets | Total Equity |
|---|---|---|---|---|---|
| FY2023 Q2 | $0 | $0 | $0 | $40.5M | $29.0M |
| FY2023 Q1 | $0 | $0 | $0 | $48.6M | $39.0M |
| FY2022 Q4 | $0 | $0 | $0 | $55.5M | $46.2M |
| FY2022 Q3 | $0 | $0 | $0 | $62.4M | $52.8M |
| FY2022 Q2 | $0 | $0 | $0 | $67.0M | $57.2M |
| FY2022 Q1 | $0 | $0 | $0 | $74.4M | $65.2M |
| FY2021 Q4 | $0 | $0 | $0 | $81.2M | $70.9M |
| FY2021 Q3 | $0 | $0 | $0 | $90.0M | $78.7M |
Frequently Asked Questions
How much cash does ZYNE have?+
Cash and equivalents for Zynerba Pharmaceuticals includes cash in bank accounts, money market funds, and short-term investments that can be quickly converted to cash. This figure comes from the company's most recent quarterly balance sheet filing.
What is Zynerba Pharmaceuticals's debt situation?+
Total debt includes all short-term and long-term borrowings reported on the balance sheet. Cannabis companies often carry higher debt loads because limited access to traditional banking forces them to use alternative financing at higher interest rates. Compare ZYNE's debt-to-equity ratio to industry peers for context.
How long can ZYNE operate at its current burn rate?+
Cash runway is estimated by dividing cash on hand by the average monthly cash burn (negative operating cash flow). For Zynerba Pharmaceuticals, this metric indicates how many months the company can continue operating without raising additional capital. Companies with less than 12 months of runway may need to raise capital soon, which could dilute shareholders.